Background: The ideal approach to monitor the haematological response of patients with anaemia associated with chronic renal failure during erythropoietin therapy is controversial. The reticulocyte haemoglobin content (CHr) and percentage hypochromic red cells (% Hypo) may be used as sensitive and specific indicators of functional iron deficiency in clinical situations with otherwise normal red cell indices. In the reticulocyte channel of a new blood cell counter using fluorescence flow cytometry, the Sysmex XE-2100, two novel parameters are determined (RBC-Y and RET-Y) by measuring the mean value of the forward scatter histograms of red cells and reticulocytes. These values seem to equate with red cell/reticulocyte haemoglobin content. Material and Methods:40 normal healthy males, 70 patients with iron deficiency (selected by indices), 90 patients with chronic renal failure before the start of dialysis or receiving continuous ambulatory peritoneal dialysis and 115 patients on long-term haemodialysis were studied on two different blood cell counters. A soluble transferrin receptor assay and measurements of ferritin were used to assess iron status. Results: A normal and iron-deficient range for RBC-Y and RET-Y has been defined and compared to the values for CHr and % Hypo. Excellent correlation between CHr and RET-Y (r = 0.94) is obtained in all groups and reasonable correlation with % Hypo and RBC-Y (r = 0.84). The soluble transferrin receptor had similar correlation with RET-Y and RBC-Y (r = 0.68) and % Hypo (r = 0.66) but less good with CHr (r = 0.55). Ferritin was an unreliable indicator of functional iron deficiency. Conclusions The two new parameters on the XE-2100 seem to indicate functional iron deficiency, correlate with soluble transferrin receptor levels and are acceptable alternatives to CHr and % Hypo on a routine haematology analyser.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.